N

Noctrix Health

Prescription wearable neuromodulation for RLS.

Director, Clinical Affairs

Full-TimeUpdated on 10/2/2026
$230k - $250k/yr+ Annual bonus
Senior, Expert
Bachelor's, Master's
Pleasanton, CA, USA
HybridHybrid position located at the Pleasanton headquarters.

About the job

Requirements
  • Bachelor’s degree in Nursing, Life Sciences, Biomedical Engineering, or a related scientific or technical discipline.
  • Minimum of 8 years of clinical affairs or clinical research experience within the medical device industry.
  • Demonstrated leadership experience managing Clinical Affairs personnel, CROs, clinical vendors, and external partners.
  • Proven experience managing medical device clinical programs from study start-up through execution and close-out.
  • Experience with multiple clinical study models, including multicenter, decentralized, and hybrid clinical trials.
  • Strong knowledge of FDA clinical trial requirements, Good Clinical Practice (ICH-GCP), ISO 14155, and applicable clinical research regulations.
  • Demonstrated experience providing sponsor oversight of medical device clinical studies.
  • Experience developing and managing clinical study budgets, timelines, enrollment forecasts, resources, and operational plans.
  • Experience supporting clinical evidence generation for regulatory submissions.
  • Strong understanding of clinical study documentation, data quality, safety reporting, monitoring, and inspection-readiness requirements.
  • Proven ability to identify and mitigate clinical program risks while managing multiple priorities and studies simultaneously.
  • Strong written and verbal communication skills with the ability to communicate clinical strategy, study performance, and risks to executive leadership.
  • Demonstrated ability to effectively collaborate across Clinical Research, Regulatory Affairs, Quality, Product Development, and other functions.
Responsibilities
  • Lead the planning, execution, and oversight of medical device clinical studies from study start-up through close-out.
  • Contribute to clinical development strategies supporting product development, regulatory submissions, reimbursement initiatives, commercialization, and post-market evidence generation.
  • Provide sponsor oversight of clinical trials, including monitoring activities, site performance, protocol compliance, enrollment, and clinical data quality.
  • Ensure clinical studies comply with applicable FDA requirements, Good Clinical Practice (GCP), ISO 14155, approved protocols, and company procedures.
  • Develop and manage study timelines, budgets, resource plans, enrollment forecasts, and key milestones.
  • Identify clinical program risks, develop mitigation strategies, and resolve operational challenges affecting study timelines, quality, or budget.
  • Lead clinical site identification, selection, initiation, engagement, performance management, and close-out activities.
  • Build and maintain relationships with investigators, study coordinators, research institutions, and other clinical partners.
  • Select, manage, and oversee CROs, clinical vendors, consultants, and service providers to meet quality, timeline, and budget expectations.
  • Support development and review of clinical study protocols, informed consent forms, case report forms, clinical reports, and other study documentation.
  • Partner with Regulatory Affairs to support regulatory submissions requiring clinical evidence and align clinical programs with regulatory strategy.
  • Ensure the integrity, completeness, quality, and traceability of clinical data and study documentation.
  • Support adverse event review, safety monitoring, clinical risk management, audits, regulatory inspections, and applicable Quality System activities.
  • Collaborate with Product Development, Quality, Regulatory Affairs, and Clinical Research to incorporate clinical insights into product development, risk management, labeling, and post-market activities.
  • Support clinical evidence generation for reimbursement, payer engagement, market access, and commercialization initiatives.
  • Establish and monitor clinical program KPIs, study performance metrics, and operational dashboards.
  • Provide executive leadership with regular updates on study progress, enrollment, budgets, risks, clinical evidence generation, and key program milestones.
  • Lead, mentor, and develop Clinical Affairs personnel while establishing clear performance expectations and promoting operational excellence.
  • Identify and implement opportunities to improve clinical processes, systems, vendor management, and study execution as the organization scales.
Desired Qualifications
  • Master’s degree or other advanced degree in a relevant scientific, clinical, or technical discipline.
  • Experience within a startup or growth-stage medical device organization.
  • Experience supporting pivotal or other clinical studies used for FDA submissions and product approvals or clearances.
  • Experience generating clinical evidence to support reimbursement, payer coverage, or market access initiatives.
  • Experience with neurological, neuromodulation, wearable, or connected medical devices.
  • Experience supporting FDA inspections, clinical site audits, and other regulatory or Quality System inspections.
  • Experience building or scaling Clinical Affairs functions, processes, and teams.
  • Experience working with international clinical studies and regulatory requirements.
  • Excellent leadership, project management, organizational, and problem-solving capabilities.

About the company

Noctrix Health makes prescription wearable therapy for Restless Legs Syndrome using the NTX100 Tonic Motor Activation System (Nidra). It uses leg bands to stimulate the peroneal nerves at night, producing gentle muscle activation that reduces RLS sensations and improves sleep. The device is prescribed through healthcare providers for adults with moderate-to-severe, medication-refractory RLS and is backed by FDA De Novo clearance in 2023 following a Breakthrough Device Designation and a multi-center trial. The goal is to establish wearable therapeutics as a standard non-drug treatment option to improve sleep for people with RLS.

Company Size

51-200

Company Stage

Acquired

Total Funding

$90.5M

Headquarters

Pleasanton, California

Founded

2018

Get referred to Noctrix Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Noctrix reached roughly $24 million annual run-rate revenue before the June 2026 close.
  • Medicare and VA access expanded in 2024-2026, strengthening patient conversion.
  • Resmed will push Nidra through its sleep physician and HME/DME channels.

What critics are saying

  • Resmed now owns Noctrix, eliminating independent-company upside for new investors and employees.
  • Coverage remains fragmented; many insurers still require case-by-case reviews and appeals, slowing sales.
  • If Resmed deprioritizes Nidra, Noctrix disappears inside a much larger sleep portfolio.

What makes Noctrix Health unique

  • Nidra is the only FDA De Novo wearable treatment for refractory RLS since 2023.
  • AASM guidelines in 2025 endorsed bilateral peroneal nerve stimulation for RLS symptoms.
  • Resmed closed the $340 million acquisition on June 1, 2026, validating market pull.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

↑ 4%

1 year growth

↑ 3%

2 year growth

↑ 0%
Sleep Review Magazine
May 5th, 2026
Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker.

Resmed to expand sleep portfolio with $340M acquisition of restless legs syndrome device maker. Resmed will acquire the manufacturer of an fda-cleared nerve stimulation device for refractory RLS, a move that leverages its existing sleep physician and home medical equipment channels. Key takeaways: * Resmed has signed an agreement to acquire Noctrix Health, maker of the Nidra device, for a purchase price of $340 million. * The acquisition targets the estimated 7% of adults globally affected by RLS, a population with meaningful overlap with obstructive sleep apnea. * The transaction is expected to close around June 1, 2026, with revenue to be reported within Resmed's Americas Devices category. Resmed has signed a $340 million agreement to acquire Noctrix Health, a medical device company with an FDA de novo classified product indicated for the treatment of refractory moderate-to-severe restless legs syndrome (RLS). The flagship product, Nidra, is a noninvasive nerve stimulation device. The acquisition marks Resmed's expansion into adjacent sleep health markets, targeting what is considered the third-most-prevalent sleep disorder after obstructive sleep apnea (OSA) and insomnia. RLS affects approximately 7% of adults globally, including around 17 million people in the US, and has a meaningful overlap with OSA. "RLS treatments from Noctrix are noninvasive, clinically proven, and drug-free, just like our CPAP/APAP and bilevel therapies," said Michael Farrell, CEO and chairman of the board at Resmed, during the company's third-quarter earnings call. Resmed, which has been an investor in Noctrix since 2024, plans to leverage its established market access to scale the therapy. Prescriptions for the device are written predominantly by sleep physicians and flow through the same home medical equipment (HME) and durable medical equipment (DME) delivery channels where Resmed currently holds a leading market share. "The reach of our Resmed brand among sleep physicians and HME providers as well as our national and international distribution channel strength makes us the best owner of this scarce asset," Farrell said. The transaction is targeted to close on or around June 1, 2026. Noctrix currently has an annual run rate revenue of approximately $24 million, which Resmed notes is growing at a faster rate and operating at a higher gross margin than Resmed's core business. Once closed, Noctrix's financials will be reported within Resmed's Americas Devices category. The acquisition is expected to result in an approximate $0.02 reduction in non-GAAP earnings per share for the fourth quarter of fiscal year 2026 as Resmed continues to invest in research and development and sales and marketing for the new asset.

Simply Wall St
May 1st, 2026
ResMed names new CFO and acquires Noctrix Health to expand into neurology

ResMed has appointed Aaron Bloomer as chief financial officer, replacing retiring CFO Brett Sandercock, and agreed to acquire Noctrix Health, a medical device company specialising in restless leg syndrome treatments. The moves mark a strategic shift for ResMed, which is primarily known for sleep apnoea devices and related software. The Noctrix acquisition expands the company's portfolio into neurological conditions affecting sleep quality, broadening its clinical scope beyond traditional respiratory care. Investors will be watching how ResMed balances capital allocation between its core sleep apnoea business and new neurology-related devices. Integration risks around Noctrix, including regulatory and reimbursement hurdles, remain key factors to monitor. At $213.81, ResMed shares trade approximately 26% below the analyst target of $288.21.

Michael West Media
May 1st, 2026
Snoring leader buys restless leg syndrome device maker - Michael West

Sleep apnoea company Resmed has acquired a California firm that makes a device for patients with restless leg syndrome, the third-biggest sleep disorder.

FinSMEs
Sep 2nd, 2025
Noctrix Health Raises Up To $33.5M in Debt and Equity Funding

Noctrix Health raises up to $33.5M in debt and equity funding.

FinancialContent
Aug 29th, 2025
Noctrix Health Raises $33.5M for RLS Therapy

Noctrix Health has raised $33.5 million to accelerate the U.S. commercialization of its Nidra® TOMAC therapy for Restless Legs Syndrome (RLS). The funding includes contributions from Blue Venture Fund, Sandbox Clinical Ventures, and a debt facility from Bridge Bank. The company has also expanded its leadership team, appointing Ivan Lubogo as Chief Commercial Officer and promoting Jonathan Charlesworth, Ph.D., to Chief Scientific Officer. Mark Verratti joins the Board of Directors.